Markets:

Overview

News

Currencies

International

Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

22.70 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Mar 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >

Breaking Down Arcus Biosciences: 4 Analysts Share Their Views ↗

August 09, 2024

Via Benzinga

RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences ↗

July 08, 2024

Via Benzinga

After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies ↗

June 03, 2024

Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 24, 2024

Via Benzinga

RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Navigating 5 Analyst Ratings For Arcus Biosciences ↗

March 25, 2024

Via Benzinga

Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know ↗

February 22, 2024

Via Benzinga

Recap: Arcus Biosciences Q4 Earnings ↗

February 21, 2024

Via Benzinga

Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity ↗

November 07, 2023

Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

October 05, 2023

On Thursday, 369 companies hit new 52-week lows.

Via Benzinga

Expert Ratings for Arcus Biosciences ↗

October 03, 2023

Via Benzinga

Where Arcus Biosciences Stands With Analysts ↗

September 12, 2023

Via Benzinga

Earnings Scheduled For February 21, 2024 ↗

February 21, 2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

Via Benzinga

Preview: Arcus Biosciences's Earnings ↗

February 20, 2024

Via Benzinga

$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

February 01, 2024

Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.

Via Benzinga

Key Takeaways From Arcus Biosciences Analyst Ratings ↗

January 30, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

January 30, 2024

We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today!

Via InvestorPlace

Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars ↗

January 30, 2024

Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy.

Via Benzinga

What 9 Analyst Ratings Have To Say About Arcus Biosciences ↗

November 08, 2023

Via Benzinga

Arcus Biosciences: Q3 Earnings Insights ↗

November 07, 2023

Via Benzinga

5 Analysts Have This to Say About Arcus Biosciences ↗

August 24, 2023

Via Benzinga

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Via Benzinga

Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update ↗

August 23, 2023

Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 23, 2023

Via Benzinga

Why Grab Holdings Are Trading Higher By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

August 23, 2023

Gainers AgileThought, Inc. (NASDAQ: AGIL) jumped 85.5% to $0.3941. AgileThought recently posted a loss for the second quarter.

Via Benzinga

How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30% ↗

August 23, 2023

Roche provided an update from its study in lung cancer using an anti-TIGIT drug.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 23, 2023

Via Benzinga

Why AMC Entertainment Shares Are Trading Lower By 21%; Here Are 20 Stocks Moving Premarket ↗

August 23, 2023

Gainers BioNexus Gene Lab Corp. (NASDAQ: BGLC) shares gained 48.5% to $2.05 in pre-market trading after jumping 30% on Tuesday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

August 23, 2023

It's time for another dive into the biggest pre-market stock movers as we break down all of the biggest news on Wednesday!

Via InvestorPlace

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

Headline News about Arcus Biosciences, Inc. Common Stock

Starting at $3.75/week.

Subscribe Today